- Home
- NATH vs PALI Comparison
NATH vs PALI Comparison
Compare NATH & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NATH | PALI |
|---|---|---|
| Founded | 1916 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.7M | 311.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NATH | PALI |
|---|---|---|
| Price | $100.77 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 55.3K | ★ 6.5M |
| Earning Date | 02-05-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 4.02 | N/A |
| EPS | ★ 5.56 | N/A |
| Revenue | ★ $154,991,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.14 | ★ N/A |
| Revenue Growth | ★ 7.82 | N/A |
| 52 Week Low | $77.92 | $0.53 |
| 52 Week High | $118.50 | $2.64 |
Technical Indicators
Market Signals| Indicator | NATH | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 67.25 | 46.74 |
| Support Level | $91.22 | $1.64 |
| Resistance Level | $101.93 | $1.90 |
| Average True Range (ATR) | 1.82 | 0.21 |
| MACD | 1.04 | -0.03 |
| Stochastic Oscillator | 91.28 | 21.86 |
Price Performance
Historical ComparisonAbout NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.